Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance

International Journal of Cardiology

Volumn 134, Issue 2, 2009, Pages 224-230

  Kuruma, Tadao ^a   Maruyama, Toru ^a   Hiramatsu, Shin ichi ^a   Yasuda, Yuichiro ^a   Yasuda, Shioto ^a   Odashiro, Keita ^a   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Amiodarone; Cytokine; Lung; Th1 Th2; Toxicity

Indexed keywords

AMIODARONE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIURETIC AGENT; GAMMA INTERFERON; INTERLEUKIN 4; SOTALOL;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HEART VENTRICLE ARRHYTHMIA; HELPER CELL; HUMAN; LOADING DRUG DOSE; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ADMINISTRATION, ORAL; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LUNG DISEASES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TACHYCARDIA, VENTRICULAR; TH1 CELLS; TH2 CELLS; VENTRICULAR FIBRILLATION;

EID: 64849091989     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.02.027     Document Type: Article

References (33)

1. Hostetler K.Y., Vande Berg J., Aldern K.A., and Brophy G.T. Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochem Pharmacol 41 (1991) 1007-1013
2. Wilson B.D., Clarkson C.E., and Lippmann M.L. Amiodarone causes decreased cell-mediated immune response and inhibits the phospholipase C signaling pathway. Lung 171 (1993) 137-148
3. Matsumori A., Ono K., Nishio R., Nose Y., and Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 96 (1997) 1386-13891
4. Magro S.A., Lawrence E.C., Wheeler S.H., Krafchek J., Lin H.T., and Wyndham C.R.C. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function test. J Am Coll Cardiol 12 (1988) 781-788
5. Dusman R.S., Stanton M.S., Miles W.M., et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82 (1990) 51-59
6. Singh S.N., Fisher S.G., Deedwania P.C., Rohatgi P., Singh B.N., and Fletcher R.D. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 30 (1997) 514-517
7. Fung R.C.Y., Chan W.K., Chu C.M., and Yue C.S. Low dose amiodarone-induced lung injury. Int J Cardiol 113 (2006) 144-145
8. Yamada Y., Shiga T., Matsuda N., Hagiwara N., and Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71 (2007) 1610-1616
9. Vorperian V.R., Havighurst T.C., Miller S., and January C.T. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30 (1997) 791-798
10. Ott M.C., Khoor A., Leventhal J.P., Paterick T.E., and Burger C.D. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 123 (2003) 646-651
11. Kay G.N., Epstein A.E., Kirklin J.K., Diethelm A.G., Graybar G., and Plumb V.J. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 62 (1988) 490-492
12. Greenspon A.J., Kidwell G.A., Hurley W., and Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 84 Suppl V (1991) III407-III415
13. Reinhart P.G., and Gairola C.G. Amiodarone-induced pulmonary toxicity in Fischer rats: release of tumor necrosis factor-α and transforming growth factor-β by pulmonary alveolar macrophages. J Toxicol Environ Health 52 (1997) 353-365
14. Chung W.H., Bennett B.M., Racz W.J., Brien J.F., and Massey T.E. Induction of c-jun and TGF-β1 in Fischer 344 rats during amiodarone-induced pulmonary fibrosis. Am J Physiol 281 (2001) L1180-L1188
15. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8 (2003) 223-246
16. Matsui S., Zong Z.P., Hna J.F., Katsuda S., Yamaguchi N., and Fu M.L.X. Amiodarone minimizes experimental autoimmune myocarditis in rats. Eur J Pharmacol 469 (2003) 165-173
17. Zong Z.P., Matsui S., Han J.F., Katsuda S., and Fu M.L. Involvement of thymus in amiodarone-treated autoimmune myocarditis in rats. Int J Cardiol 125 (2008) 122-129
18. Endoh Y., Hanai R., Uto K., et al. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 86 (2000) 229-231
19. Jung T., Schauer U., Heusser C., Neumann C., and Riegger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159 (1993) 197-207
20. Brien J.F., Jimmo S., Brennan F.J., Ford S.E., and Armstrong P.W. Distribution of amiodarone and its metabolite, desethyamiodarone, in human tissues. Can J Physiol Pharmacol 65 (1987) 360-364
21. Breytenbach U., Clark A., Lamprecht J., and Bouic P. Flow cytometric analysis of the Th1-Th2 balance in healthy individuals and patients infected with the human immunodeficiency virus (HIV) receiving a plant sterol/sterolin mixture. Cell Biol Int 25 (2001) 43-49
22. Maruyama T., Kishikawa T., Ito H., Kaji Y., Sasaki Y., and Ishihara Y. Augmentation of pulmonary vein backflow velocity during left atrial contraction: a novel phenomenon responsible for progression of atrial fibrillation in hypertensive patients. Cardiology 109 (2008) 33-40
23. Kulmatycki K.M., and Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharmaceut Sci 8 (2005) 602-625
24. Fuse K., Kodama M., Ito M., et al. Polarity of helper T cell subsets represents disease nature and clinical course of experimental autoimmune myocarditis in rats. Clin Exp Immunol 134 (2003) 403-408
25. Hasegawa H., Takano H., Zou Y., et al. Pioglitazone, a peroxisome proliferator-activated receptor γ activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol 38 (2005) 257-265
26. Methe H., Brunner S., Wiegand D., Nabauer M., Koglin J., and Edelman E.R. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 45 (2005) 1939-1945
27. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
28. Huaux F., Liu T., McGarry B., Ullenbruch M., and Phan S.H. Dual roles of IL-4 in lung injury and fibrosis. J Immunol 170 (2003) 2083-2092
29. Herring A.C., Hernandez Y., Huffnagle G.B., and Toews G.B. Role and development of TH1/TH2 immune response in the lungs. Semin Respir Crit Care Med 25 (2004) 3-10
30. Satoh S., Oyama J., Suematsu N., et al. Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. Int J Cardiol 111 (2006) 405-412
31. Setsuta K., Seino Y., Ogawa T., Ohtsuka T., Seimiya K., and Takano T. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 68 (2004) 747-750
32. Akoun G.M., Cadranel J.L., Blanchette G., Milleron B.J., and Mayaud C.M. Bronchoalveolar lavage cell data in amiodarone-associated pneumonitis. Evaluation in 22 patients. Chest 99 (1991) 1177-1182
33. Uhal B.D., Wang R., Laukka J., Zhuang J., Soledad-Conrad V., and Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol 92 (2003) 81-87